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JAK/STAT signalling is essential for anti-viral immunity, making IFN-a an obvious anti-viral thera-
peutic. However, many HCV+ patients fail treatment, indicating that the virus blocks successful
IFN-a signalling. We found that STAT1 and STAT3 proteins, key components of the IFN-a signalling
pathway were reduced in immune cells and hepatocytes from HCV infected patients, and upon HCV
expression in Huh7 hepatocytes. However, STAT1 and STAT3 mRNA levels were normal. Mechanistic
analysis revealed that in the presence of HCV, STAT3 protein was preferentially ubiquitinated, and
degradation was blocked by the proteasomal inhibitor MG132. These ﬁndings show that HCV inhib-
its IFN-a responses in a broad spectrum of cells via proteasomal degradation of JAK/STAT pathway
components.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The anti-viral properties of interferon (IFN)-a have made it an
obvious therapeutic agent to combat HCV infection, a major cause
of chronic liver disease, hepatocellular carcinoma and liver trans-
plantation [1]. Unfortunately, IFN-a therapy has a high failure rate,
particularly in patients infected with genotype 1, with as few as
30% responding to treatment, suggesting that HCV might target
this pathway [2]. Several molecular mechanisms by which HCV
evades the immune response have already been described. HCV
blocks adaptive immunity, by stimulating speciﬁc T regulatory
cells [3], as well as inhibiting normal T cell migration and IL-2
secretion [4,5]. More recently, attention has turned to the innate
immune response and HCV has been shown to target NK cell activ-
ity, dendritic cell function [6,7] and pathogen recognition path-
ways, including inhibition of Toll-Like Receptor (TLR)-3 and
retinoic acid-inducible gene (RIG)-I signalling [8]. However, thereasons for non-response to endogenous or therapeutic IFN-a re-
main poorly deﬁned.
Anti-viral signalling commences upon IFN-a engagement with
its receptor, thus activating tyrosine kinases, which phosphorylate
receptor docking sites for cytoplasmic signal transducer and acti-
vator of transcription (STAT) proteins. STATs become phosphory-
lated, form dimers and translocate to the nucleus, where they
bind speciﬁc DNA-recognition motifs, promoting gene transcrip-
tion. Disruption of STAT genes in mice has conﬁrmed that these
proteins are essential in several biological processes, including cell
growth and differentiation, as well as immune defence [9,10]. IFN-
a signalling via STAT proteins leads to the upregulation of over 500
IFN Sensitive Genes (ISGs), including key anti-viral and pro-inﬂam-
matory mediators [11–14].
Signal transduction is often regulated by the homeostatic pro-
cess of protein turnover via degradation of poly-ubiquitinated pro-
teins through the 26S proteasome. Suppressor of cytokine
signalling (SOCS) proteins associate with elongin B, elongin C, cul-
lin (cul) and the RING ﬁnger-containing protein, to form functional
Elongin B/C-cul-SOCS box (ECS)-like E3 ligase complexes, that cata-
lyse ubiquitin transfer to target proteins [15]. Viral proteins regu-
larly act as E3 ligase proteins; in fact, we and others have shown
Table 1
Primer sequences used for quantitative and qualitative RT-PCR.
qRT-PCR primers
RPS15 F CGGACCAAAGCGATCTCTTC
RPS15 R CGCACTGTACAGCTGCATCA
STAT3 F GAGAAGGACATCAGCGGTAAGAC
STAT3 R GCTCTCTGGCCGACAATACTTT
STAT1 F TGATGGCCCTAAAGGAACTG
STAT1 R AGGAAAACTGTCGCCAGAGA
RT-PCR primers
B-actin F GGACTTCGAGCAAGAGATGG
B-actin R AGCACTGTGTTGGCGTACAG
STAT1 F CCGTTTTCATGACCTCCTGT
STAT1 R TGAATATTCCCCGACTGAGC
STAT3 F TTTCACTTGGGTGGAGAAGG
STAT3 R GCTACCTGGGTCAGCTTCAG
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target STAT proteins for degradation via the proteosome [16–18].
Since many HCV-infected patients do not respond to IFN-a ther-
apy we investigated the status of the JAK/STAT pathway in both
primary immune cells and hepatocytes from HCV infected patients.
We found that STAT1 and STAT3 proteins were reduced in all major
immune cell populations and hepatocytes from HCV+ patients.
Furthermore, we discovered that STAT3 was preferentially ubiqui-
tinated and targeted for proteosomal degradation in the presence
of HCV. These ﬁndings demonstrate for the ﬁrst time that essential
anti-viral components of the IFN-a pathway are reduced in both
immune cells and hepatocytes, revealing a novel mechanism by
which HCV blocks responsiveness to IFN-a therapy.
2. Patients
Blood from 17 patients (15 female, 2 male, ranging between 32
and 71 years of age) who were PCR positive for HCV (Supplemen-
tary Table 1) and had not undergone IFN-a/Ribavrin standard
treatment of care, were studied. All were informed and gave writ-
ten consent. The study received ethical approval from the Research
and Ethics Committee at SVUH, in accordance with the guidelines
of the 1975 Declaration of Helsinki. Patients were tested for HCV
antibodies using enzyme immunoassays (Abbott) and immunoblot
assays (Chiron Corp., USA).
3. Materials and methods
3.1. PBMC isolation
PBMCs were isolated from 30 ml of blood by centrifugation
(650g for 30 min) over Ficoll (Amersham, UK) and washed X2
(290g for 10 min) with RPMI.
3.2. HCV RNA detection in PBMCs
PBMCs (resuspended in stabilising solution RNAlater (Ambion,
UK)) were lysed according to the Magna Pure external lysis proto-
col (Roche, UK) and cellular RNA from 1.5  106 cells was ex-
tracted; real time qRT-PCR performed according to the COBAS
Taqman protocol HCV test v2.0 (Roche, UK). HCV titre recorded
as international units (IU).
3.3. Cell culture
Huh7 cells were grown in DMEM supplemented with 6 lg/ml
zeocin. PBMCs were cultured in RPMI containing 2% FCS, 250U/
ml penicillin and 250 lg/ml streptomycin. Cells were treated with
1000 U/ml human IFN-a (Roche, Switzerland) and 10 lM MG132
(Calbiochem, USA).
3.4. Transfection
Huh7 cells expressing T7 polymerase were transfected for 16 h
using Lipofectamine 2000 (Invitrogen, USA), with 0.75 lg (6 well
plates) or 5 lg (9 cm diameter plates) of pBRTM/HCV1-3011 DNA
construct (a kind gift from Prof. Charles Rice, The Rockefeller Univer-
sity) or EV (Invitrogen, USA) or with 0.1 lg of DNA in poly-D-lysine
slides (Becton Dickson, USA). Huh7 cells were also transfected with
5 lg HA-tagged-Ubiquitin or EV for 48 h using Lipofectamine 2000.
3.5. Immunoprecipitation
Huh7 cells, transfected with EV/HCV (5 lg) /+MG132 treat-
ment, or transfected with HA-Ubiquitin and HCV, were harvested
in mild lysis buffer (50 mM Hepes, 100 mM NaCl, 1 mM EDTA,10% glycerol, 0.5% NP40) or RIPA buffer, substituted with aprotinin
[5 lg/ml], leupeptin [5 lg/ml], PMSF [1 mM], Na3VO4 [1 mM]). Ly-
sates were immunoprecipitated with protein-A agarose beads and
STAT3 antibody, before immunoblotting for HA (Sigma, USA), ubiq-
uitin or STAT3 (Santa Cruz Biotechnologies, USA).
3.6. Immunoblotting
Cells were harvested in lysis buffer and analysed by immuno-
blotting using pSTAT1, pSTAT3, STAT1 (New England Biolabs,
USA), STAT3, ubiquitin (Santa Cruz Biotechnologies, USA), HCV-
NS2, b-actin, c-tubulin, HA (Sigma, USA), HCV-E2 (Acris, USA),
HCV-Core (Abcam, UK) and secondary antibodies labelled with
infrared dyes and the infrared Odyssey imager. Densitometry was
calculated using LI-COR software. (LI-COR, Germany).
3.7. RT-PCR
RNA was isolated from cells following the Trizol manufacturer’s
protocol (Invitrogen, USA). RT-PCR was performed using the One-
step protocol (Qiagen, Germany). Cycling parameters: 30 min at
50 C, 95 C for 15 min and 35 cycles of 94 C, 58 C and 72 C for
30 s, 72 C for 10 min. qRT-PCR: as described before [19]. Human
gene ampliﬁcations normalised to Ribosomal protein 15 (RPS15);
Primers listed in Table 1.
3.8. HCV infection
Virus stock production as described previously [20]. In vitro
transcribed Jc1 RNA was electro-transfected into Huh7.5 cells
and supernatants collected 24, 48 and 72 h post transfection,
pooled and infectious titer determined by TCID50. Huh7.5 cells
were inoculated with infectious supernatants (MOI = 3) for 24 h,
washed with DMEM and treated with MG132 or DMSO. After 2 h,
cells were harvested and lysed in 50 ll RIPA.
3.9. Immunohistochemistry
Liver sections (8 lm) were cut from parafﬁn-embedded, forma-
lin-ﬁxed samples and microwaved in a pressure cooker in sodium
citrate buffer (27 ml 0.1 M citric acid, 123 ml 0.1 M tri sodium
citrate in 1500 ml dH2O, pH 6). Sections were stained using
STAT3(Santa Cruz Biotechnologies, USA) and STAT1 (New England
Biolabs) antibodies (1:80) for 1 h in antibody diluent (DAKO, Den-
mark) and detected using a polymer detection kit (Leica Microsys-
tems, Germany) and analysed by microscopy.
3.10. Immunoﬂuorescence
As described previously [19], antibodies included anti-STAT3
(Santa Cruz Biotechnologies, USA) labelled with Alexa 568 or 546
Fig. 1. STAT1 and STAT3 protein levels are reduced in PBMCs from HCV+ patients. (A) Lysates from PBMCs of individual HCV+ or healthy subjects, treated /+ IFN-a for
15 min, were analysed by immunoblotting for total or phosphorylated STAT1, STAT3 and b-actin (n = 3). STAT1 and STAT3 mRNA levels in PBMCs from HCV+ and healthy
individuals were measured by (B) qualitative RT-PCR (HCV n = 6; healthy n = 4) and (C) quantitative qRT-PCR (healthy n = 7; HCV n = 12). (D) Ratio of STAT3: house-keeping
protein optical density (OD) measured by densitometric analysis of immunoblots of STAT3 and b-actin or c-tubulin protein levels in PBMCs from HCV+ (n = 17) and healthy
(n = 8) individuals. (E) Immunoblot of HCV-NS2 and b-actin from healthy (H) (n = 3) and HCV+ patient PBMC lysates (n = 3). (F) qRT-PCR detection of HCV RNA in PBMCs from
5 HCV RNA+ individuals (patient numbers 1–5 inclusive), 2 HCV RNA negative patients (patient 6 spontaneously cleared HCV and patient 7 cleared HCV during IFN-a/
ribavirin therapy) and 2 healthy controls (patient numbers 8 and 9).
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Fig. 2. STAT1 and STAT3 proteins are reduced in major immune cell lineages of HCV+ patients. PBMCs from healthy (n = 3) or HCV+ individuals (n = 7) were labelled with
CD45, CD3, CD19, CD56, CD14, CD16 and HLA-DR antibodies. Cells were ﬁxed, permeabilised and stained with (A) STAT1 and (B) STAT3 antibodies. Representative dot plots of
a healthy and a HCV+ individual shown. (C) Confocal micrographs of PBMCs from HCV+ individuals labelled with HCV-E2 along with FITC labelled CD19, HLA-DR and CD14 or
CD56 and CD3 primary antibodies (n = 2). Nucleus labelled with DAPI. Bar, 10 lm.
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(Sigma, USA) were used. DNA was stained using Prolong gold
anti-fade reagent containing DAPI (Invitrogen, CA, USA). HCV-E2
(Acris, USA) and Alexa 546 or 488 secondary; CD56, CD3 and Alexa
647 secondary and FITC-conjugated antibodies to: CD19, CD14, and
HLA-DR (BD biosciences, USA) were used. Microscopy was per-
formed on an Olympus FV1000 laser scanning confocal microscope,
using an UPlanSAPO 60X/1.35 NA oil objective at room tempera-
ture. Cells were digitally sectioned by confocal laser scanning ﬂuo-
rescence microscopy at 0.3 lm per slice and analyzed using the
Olympus FV1000 software.3.11. Flow cytometry
PBMCs were surface labelled with FITC-conjugated antibodies
to: CD45, CD19, CD14, CD16 and HLA-DR; PerCP-conjugated anti-
CD3 or Alexa-Fluor 488-conjugated anti-CD56 (BD Biosciences,
USA). Cells were ﬁxed with 4% paraformaldehyde for 30 min on
ice, washed X2 in PBS and resuspended in permeabilisation buffer
(eBioscience). Cells were incubated with STAT1-PE and STAT3-APC
(BD Biosciences, USA) for 30 min, washed in PBS and acquired
using a Dako Cyan ﬂow cytometer. Data was analysed using Flowjo
software (Tree Star Inc, USA).
Fig. 3. Loss of STAT1 and STAT3 protein in hepatocytes and liver inﬁltrating
leukocytes. (A) Immunoblot of STAT1, STAT3, HCV-NS2 and b-actin protein in Huh7
cells transfected /+ HCV DNA construct or EV control. (B) qRT-PCR of STAT1 and
STAT3 mRNA in Huh7 hepatocytes transfected with EV or HCV constructs (n = 3).
(C) Immunohistochemistry of STAT1 and STAT3 in liver tissue from HCV+
(representative of 3 individuals) and healthy individuals (representative of 3
individuals). Bar, 50 lm.
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Statistical analysis was performed using GraphPad Prism ver-
sion 5.01 for Windows (GraphPad Software, La Jolla, CA, USA).
Groups were compared by paired Student’s T-test for parametric
samples with GAUSSIAN distribution, non-parametric Mann-Whitney
analysis for patient samples and ANOVA with Bonferroni’s multiple
comparison post-test analysis as appropriate. ⁄P < 0.05, ⁄⁄P < 0.01,
⁄⁄⁄P < 0.001.
4. Results
4.1. STAT1 and STAT3 proteins are reduced in PBMCs from HCV+
individuals
To investigate the status of the JAK/STAT pathway in HCV pa-
tients, we initially analysed STAT1 and STAT3 tyrosine phosphory-
lation and protein levels in human PBMCs from HCV positive (+)
and healthy individuals. We found that protein levels were lower
in PBMCs from HCV+ patients compared to healthy controls
(Fig. 1A), and IFN-a-induced tyrosine phosphorylation of both
STAT1 and STAT3 proteins were lower, although mRNA levels did
not differ signiﬁcantly (Fig. 1B and C). Since this was the ﬁrst dem-
onstration of STAT3 protein reduction in HCV infected cells, protein
levels were investigated in 16 additional treatment-naïve HCV+
(genotype 1) patients and 8 healthy controls. Densitometric analy-
sis revealed that STAT3 protein levels were signiﬁcantly lower in
PBMCs from HCV+ patients compared to healthy controls(P < 0.001) Fig. 1D). Interestingly, we found HCV-NS2 protein by
immunoblotting (Fig. 1E) and HCV RNA by qRT-PCR (Fig. 1F) within
PBMCs from HCV+ patients, indicating that intracellular HCV may
directly act to promote loss of STAT proteins.
4.2. STAT1 and STAT3 proteins are reduced in all major immune cell
populations
To determine if STAT1 and STAT3 in PBMCs were depleted from
all major immune cell types, we analysed protein levels within
speciﬁc immune cell populations using ﬂow cytometry. Normal
levels of STAT1 (Fig. 2A) and STAT3 (Fig. 2B) were observed in all
the major peripheral blood cell subsets from healthy controls,
but were signiﬁcantly reduced in all cell subsets from HCV+ pa-
tients, including monocytes (CD14+), T cells (CD3+), B cells
(CD19+), natural killer (NK) cells (CD56+), and HLA-DR+ antigen
presenting cells (APCs), demonstrating that loss of STAT protein
expression was not limited to any particular cell type (Fig. 2A
and B). Furthermore, HCV was detected by confocal microscopy
in all major immune cells types, demonstrating that its potential
to directly target intracellular STAT expression (Fig. 2C).
4.3. HCV-mediated loss of STAT1 and STAT3 in hepatocytes and liver
inﬁltrating leukocytes
To determine the effect of HCV upon STAT1 and STAT3 levels in
liver cells, we next analysed their expression in Huh7 hepatocytes
transfected with a HCV DNA construct. We found considerably re-
duced levels of STAT1 and STAT3 protein (Fig. 3A) in HCV transfec-
ted hepatocytes and as in PBMCs, mRNA levels were not
signiﬁcantly different (Fig. 3B). We further analysed STAT1 and
STAT3 in primary human liver tissue by immunohistochemistry
and found STAT1 and STAT3 levels greatly reduced in hepatocytes
and inﬁltrating leukocytes of HCV+ livers, compared to healthy
controls (Fig. 3C). Loss of STAT1 and STAT3 proteins in PBMCs,
Huh7 hepatocytes, primary hepatocytes and liver inﬁltrating leu-
kocytes demonstrates a conserved reduction across a spectrum of
cell types and reveals STAT3, for the ﬁrst time, as a target for HCV’s
immune evasion mechanisms.
4.4. HCV promotes STAT3 degradation via the proteasome
We and others have shown that the ubiquitin/proteasome sys-
tem is used by viruses to degrade STAT proteins [17,18] and since
STAT1 had already been shown to be proteasomally degraded by
HCV [21], we investigated the molecular mechanism responsible
for the absence of STAT3 by blocking proteasomal activity with
the inhibitor, MG132. Using immunoblotting and confocal micros-
copy, we found that absent STAT3 protein could be recovered in
PBMCs from HCV+ patients following proteasomal inhibition
(Fig. 4A and B). To determine if the loss of STAT3 in HCV transfec-
ted hepatocytes was also proteasome-dependent, we transfected
Huh7 hepatocytes with a HCV construct and treated with
MG132. We observed that HCV-mediated degradation of STAT3
was blocked by proteasomal inhibition (Fig. 4C and D). While
HCV infection with cell cultured HCV (HCVcc) had no effect on
STAT3 mRNA expression (Fig. 4E), it promoted STAT3 protein deg-
radation, which was inhibited by MG132, further conﬁrming a
HCV-controlled mechanism of STAT3 degradation via the protea-
some (Fig. 4F).
4.5. HCV enhances ubiquitination of STAT3
Since ubiquitinated proteins are targeted for proteasomal deg-
radation, we analysed protein ubiquitination in HCV expressing
Huh7s. We found that endogenous total protein ubiquitination in
Fig. 4. HCV promotes STAT3 ubiquitination and proteasomal degradation. (A) STAT3 immunoblot and (B) confocal micrograph of PBMCs from HCV+ and healthy individuals
treated /+ MG132 for 4 h (n = 3). STAT3 and the nucleus labelled with FITC and DAPI, respectively. Bar, 10 lm. (C) Immunoblot of STAT3, c-tubulin and HCV-NS2 protein
expression, /+ HCV–DNA transfection of Huh7 hepatocytes, /+ MG132 (n = 3). (D) Confocal micrograph of STAT3, HCV-Core and the nucleus (N), labelled with FITC, Alexa
568 and DAPI, respectively, /+ HCV construct expression, alongside MG132 treatment (n = 3). Bar, 10 lm. (E) STAT3 mRNA from Huh7 cells mock or HCVcc infected (n = 6).
(F) Immunoblot of STAT3, HCV-Core and c-tubulin proteins from Huh7 cells mock or HCVcc infected and treated /+ MG132 for 4 h (n = 4). (G) Immunoblot of Huh7 cells
mock or HCVcc infected and treated /+ MG132 for 4 h, whole cell lysates (WCLs) probed with ubiquitin and c-tubulin antibodies (n = 3). Values below the blot represent
densitometric analysis. Ubiquitinated protein band intensity was normalised to c-tubulin band intensity and all values are presented relative to uninfected control cells (lane
1), which was normalised to 1. (H) Huh7 cells mock or HCVcc infected treated with MG132 for 4 h were lysed and immunoprecipitated for STAT3 and immunoblotted for
ubiquitin. (I) Huh7 cells transfected /+ HCV-DNA, Ubiquitin-HA or EV constructs and treated with MG132 for 4 h were lysed, immunoprecipitated for STAT3 and
immunoblotted for HA and STAT3. WCLs probed for HCV-E2 and b-actin (n = 3).
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controls and treatment of HCV infected cells with MG132 further
increased protein ubiquitination (Fig. 4G). To determine if STAT3
ubiquitination was speciﬁcally enhanced by HCV, lysates from
Huh7 cells infected with HCVcc infected hepatocytes, /+
MG132, were immunoprecipitated for STAT3 and immunoblotted
for ubiquitin. While proteasomal inhibition with MG132 increased
levels of ubiquitinated STAT3 (Fig. 4H, lane 4), HCV infection fur-
ther enhanced levels of ubiquitinated STAT3, as seen by the pres-
ence of multiple bands increasing in molecular weight,
characteristic of polyubiquitination (Fig. 4H, lane 3). To further
analyse the speciﬁc ubiquitination of STAT3, we over-expressed
hemagglutinin (HA)-tagged ubiquitin, /+ transfection with HCV
DNA construct, in Huh7 cells, before immunoprecipitating for
STAT3 and immunoblotting for ubiquitin. Once again, STAT3 ubiq-
uitination was enhanced in HCV expressing cells, compared to con-
trols (Fig. 4I). These results indicate that HCV promotes the direct
ubiquitination of STAT3, revealing the novel mechanism by which
HCV promotes STAT3 protein degradation via the proteosome.5. Discussion
This study describes the loss of STAT1 and STAT3 from HCV-in-
fected immune cells and hepatocytes, and the mechanism by
which HCV promotes STAT3 degradation through the proteosome,
a process also used by other viruses, such as RSV, to evade immu-
nity [17].
Since HCV is hepatotrophic, previous studies have focused on
signalling pathways within hepatocytes [22]. However, because
circulating and liver inﬁltrating immune cells play such a vital role
in ﬁghting HCV infection [23] and HCV has also been identiﬁed in
immune cells [24], we investigated the IFN-a JAK/STAT pathway in
the whole PBMC population and the major individual immune cell
subgroups. In fact, we found that STAT1 and STAT3 proteins were
absent from circulating and liver inﬁltrating immune cells of HCV
patients, demonstrating widespread disruption of the anti-viral
IFN-a pathway, which identiﬁes the broad immune evasion strat-
egy of HCV and widens our understanding of this virus’s spectrum
of target cells.
Although STAT3 is known to be activated by IFN-a, its role in
this pathway remains poorly understood. Several studies, using
transformed or primary hepatocytes, suggest that HCV either acti-
vates STAT3 [25–29], has no impact [30–32] or blocks DNA binding
[33]. However, this study indicates that HCV decreases STAT3 pro-
tein in PBMCs, liver inﬁltrating leukocytes and hepatocytes from
infected patients, as well as Huh7 hepatocytes transfected or in-
fected with HCV. These data support the results of studies showing
decreased STAT3 mRNA and protein in the HCV replicon system
[34,35]. However, unlike these previous reports, we discovered
that HCV does not target STAT3 mRNA. Rather, we found that
STAT3 mRNA in Huh7 cells was elevated upon HCV expression,
suggesting a homeostatic mechanism that attempts to replace
the STAT3 protein lost during HCV-mediated proteosomal
degradation.
STAT3 is well known to promote cell proliferation and thus tu-
mour progression [36]; properties that are demonstrated in the li-
ver, with increases in hepatic STAT3 activation linked to liver
regeneration, ﬁbrosis and hepatocellular carcinoma [25,37]. How-
ever, even though STAT1 is well documented as an anti-viral medi-
ator [38], as evidenced by STAT1 KO mice lacking IFN-a
responsiveness and exhibiting increased susceptibility to viral
infection [9,39], STAT3’s role in anti-viral signalling is disputed.
Interestingly STAT3 was ruled out as an anti-viral mediator be-
cause STAT3 homo-dimers remain inducible in STAT1/ mice
that succumb to viral infections. However, STAT1:STAT1 homo-dimers and STAT1:STAT3 dimers also could not form in STAT1/
mice [9], indicating a possible role for this hetero-dimer complex
in anti-viral signalling. The functions of these STAT1:STAT3 hetero-
dimers are not known, however the loss of STAT1 and STAT3 in
HCV-infected cells may further indicate their important role during
anti-viral signalling.
In conclusion, we have shown that both STAT1 and STAT3 are
reduced in primary immune cells and hepatocytes of HCV+ pa-
tients and upon in vitro HCV expression or infection of hepato-
cytes. We have also provided evidence of HCV-mediated
ubiquitination and proteasomal degradation of STAT3, which out-
lines a basic viral immune evasion mechanism used by HCV to
block the IFN-a JAK/STAT pathway in immune cells and hepato-
cytes. This broad HCV-mediated immune evasion strategy may ex-
plain poor responsiveness to therapeutic IFN-a and highlights a
potenital target pathway for therapeutic restoration of anti-viral
immune responses.
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